Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit
Fluidigm Corporation (Nasdaq: FLDM), a leading biotechnology tools provider, will participate in the UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021, in Laguna Beach, California. The panel presentation at 8:00 p.m. ET features a customer discussing Fluidigm Imaging Mass Cytometry™ and includes participation from Chris Linthwaite, President and CEO, and Vikram Jog, CFO. Fluidigm develops multi-omic solutions for cancer and immunology, aiming to enhance health insights and therapy effectiveness.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor event:
UBS Genomics 2.0 and MedTech Innovations Summit
Wednesday, August 11, 2021
Laguna Beach, California
Panel presentation at 8:00 p.m. ET, 5:00 p.m. PT
The panel presentation includes a Fluidigm Imaging Mass Cytometry™ customer discussing spatial imaging. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will also participate in investor meetings.
About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, Advanta, and CyTOF are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for Use under Emergency Use Authorization Only. Rx Only. Other Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Contacts:
Investors:
Peter DeNardo
415 389 6400
IR@fluidigm.com
Media:
Mark Spearman
Senior Director, Corporate Communications
650 243 6621
mark.spearman@fluidigm.com
FAQ
When will Fluidigm Corporation participate in the UBS Genomics 2.0 and MedTech Innovations Summit?
What time is Fluidigm's panel presentation at the UBS Summit?
Who from Fluidigm will present at the UBS Genomics Summit?
What technologies does Fluidigm focus on in their research?
What is the primary goal of Fluidigm Corporation?
